During the past decade, Stanford Cancer Institute conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 44 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 25 clinical trials were completed. i.e. 147.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stanford Cancer Institute" #1 sponsor was "Stanford University" with 18 trials, followed by "Children's Oncology Group" with 11 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored, "Pfizer" with 8 trials sponsored and "Kite, A Gilead Company" with 8 trials sponsored. Other sponsors include 69 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stanford Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "Stanford University" with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "Celgene Corporation" with 2 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 46 trials.

According to Clinical.Site data, the most researched conditions in "Stanford Cancer Institute" are "Lymphoma" (7 trials), "Prostate Cancer" (5 trials), "Breast Neoplasms" (4 trials), "Glioblastoma" (4 trials) and "Leukemia" (4 trials). Many other conditions were trialed in "Stanford Cancer Institute" in a lesser frequency.

Most popular intervention types in "Stanford Cancer Institute" are "Drug" (96 trials), "Biological" (19 trials), "Radiation" (12 trials), "Procedure" (10 trials) and "Other" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Atezolizumab" (7 trials), "radiation therapy" (5 trials), "Bevacizumab" (4 trials) and "Cyclophosphamide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Stanford Cancer Institute" are 107 trials for "All" genders, 11 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Stanford Cancer Institute". 2 are not yet recruiting, 12 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in Stanford Cancer Institute, 3 suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Stanford Cancer Institute, 32 "Phase 1" clinical trials were conducted, 59 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".